Neil J Grey1, George A Perdrizet. 1. Department of EMS/Trauma, Medicine, and Surgery, Hartford Hospital and University of Connecticut Health Center, Hartford, Connecticut, USA.
Abstract
OBJECTIVE: To investigate whether hyperglycemia in glucose-intolerant patients without diabetes could lead to increased nosocomial infections in the surgical intensive-care unit (ICU). METHODS: A prospective, randomized, controlled clinical trial was conducted in the surgical ICU of a large teaching hospital in Hartford, Connecticut. Adult patients admitted to a 12-bed surgical ICU requiring treatment of hyperglycemia (glucose values > or = 140 mg/dL) were randomly assigned to receive standard insulin therapy (target glucose range, 180 to 220 mg/dL) or strict insulin therapy (target glucose range, 80 to 120 mg/dL) throughout their ICU stay. Demographic data, comorbidities, and confounding variables were analyzed. Outcome measures included mean daily serum glucose values, mean daily insulin doses, and number of nosocomial infections during the ICU stay. RESULTS: The study was completed by 61 critically ill surgical patients (27 in the standard glucose control group and 34 in the strict glucose control group). A significant reduction (P<0.001) in mean daily glucose level was achieved in the strict glycemic control group (125 +/- 36 mg/dL) in comparison with the standard glycemic control group (179 +/- 61 mg/dL). Furthermore, a significant reduction (P<0.05) in the incidence of total nosocomial infections, including intravascular device, bloodstream, intravascular device-related bloodstream, and surgical site infections, was observed in the strict glucose control group in comparison with the standard glucose control group. The incidence of hypoglycemia (glucose levels <60 mg/dL) was significantly increased (P<0.001) in the strict glycemic control group in comparison with the standard glycemic control group (32% versus 7.4% of patients or 0.8% versus 0.1% of total serum glucose values, respectively). CONCLUSION: Strict glycemic control is a safe and effective method for reducing the incidence of nosocomial infections in a predominantly nondiabetic, general surgical ICU patient population.
RCT Entities:
OBJECTIVE: To investigate whether hyperglycemia in glucose-intolerantpatients without diabetes could lead to increased nosocomial infections in the surgical intensive-care unit (ICU). METHODS: A prospective, randomized, controlled clinical trial was conducted in the surgical ICU of a large teaching hospital in Hartford, Connecticut. Adult patients admitted to a 12-bed surgical ICU requiring treatment of hyperglycemia (glucose values > or = 140 mg/dL) were randomly assigned to receive standard insulin therapy (target glucose range, 180 to 220 mg/dL) or strict insulin therapy (target glucose range, 80 to 120 mg/dL) throughout their ICU stay. Demographic data, comorbidities, and confounding variables were analyzed. Outcome measures included mean daily serum glucose values, mean daily insulin doses, and number of nosocomial infections during the ICU stay. RESULTS: The study was completed by 61 critically ill surgical patients (27 in the standard glucose control group and 34 in the strict glucose control group). A significant reduction (P<0.001) in mean daily glucose level was achieved in the strict glycemic control group (125 +/- 36 mg/dL) in comparison with the standard glycemic control group (179 +/- 61 mg/dL). Furthermore, a significant reduction (P<0.05) in the incidence of total nosocomial infections, including intravascular device, bloodstream, intravascular device-related bloodstream, and surgical site infections, was observed in the strict glucose control group in comparison with the standard glucose control group. The incidence of hypoglycemia (glucose levels <60 mg/dL) was significantly increased (P<0.001) in the strict glycemic control group in comparison with the standard glycemic control group (32% versus 7.4% of patients or 0.8% versus 0.1% of total serum glucose values, respectively). CONCLUSION: Strict glycemic control is a safe and effective method for reducing the incidence of nosocomial infections in a predominantly nondiabetic, general surgical ICU patient population.
Authors: Jean-Charles Preiser; Philippe Devos; Sergio Ruiz-Santana; Christian Mélot; Djillali Annane; Johan Groeneveld; Gaetano Iapichino; Xavier Leverve; Gérard Nitenberg; Pierre Singer; Jan Wernerman; Michael Joannidis; Adela Stecher; René Chioléro Journal: Intensive Care Med Date: 2009-07-28 Impact factor: 17.440
Authors: Grant V Bochicchio; Brian R Hipszer; Michelle F Magee; Richard M Bergenstal; Anthony P Furnary; Angela M Gulino; Michael J Higgins; Peter C Simpson; Jeffrey I Joseph Journal: J Diabetes Sci Technol Date: 2015-06-01
Authors: Gerd G Gauglitz; Tracy E Toliver-Kinsky; Felicia N Williams; Juquan Song; Weihua Cui; David N Herndon; Marc G Jeschke Journal: Crit Care Med Date: 2010-01 Impact factor: 7.598
Authors: J R Roberson; H L Spraker; J Shelso; Y Zhou; H Inaba; M L Metzger; J E Rubnitz; R C Ribeiro; J T Sandlund; S Jeha; C-H Pui; S C Howard Journal: Leukemia Date: 2008-10-16 Impact factor: 11.528
Authors: M Todd Greene; Robert Chang; Latoya Kuhn; Mary A M Rogers; Carol E Chenoweth; Emily Shuman; Sanjay Saint Journal: Infect Control Hosp Epidemiol Date: 2012-08-23 Impact factor: 3.254
Authors: Sean M Bagshaw; Rinaldo Bellomo; Michael J Jacka; Moritoki Egi; Graeme K Hart; Carol George Journal: Crit Care Date: 2009-06-17 Impact factor: 9.097